NCT01240382View on ClinicalTrials.gov

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

PHASE3CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

Not specified

Primary Completion Date

February 29, 2008

Conditions
Dry Eye
Interventions
DRUG

3% DE-089 ophthalmic solution

DRUG

0.1% sodium hyaluronate ophthalmic solution

Trial Locations (1)

Unknown

Santen study sites, Osaka

All Listed Sponsors
lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY

NCT01240382 - Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye | Biotech Hunter | Biotech Hunter